Inventor · disambiguated record
Steven Petrou
Also filed as: PETROU STEVEN · PETROU STEVEN P
7 granted patents·14 pending applications·9 citations·filing 2004–2025
75Inventor score
Files withPRAXIS PREC MEDICINES INC5THE FLOREY INST OF NEUROSCIENCE AND MENTAL HEALTH5PETROU STEVEN2ROGCON INC2BIONOMICS LTD1
Top patents by PatentIndex Score
21 records- 0180US8697155B2Treatment of obesity and related disordersLEVY MICHAEL J·Filed 2009·Granted Apr 15, 2014·4 cites·11 claims
- 0270US7723027B2Methods for the diagnosis and treatment of epilepsyBIONOMICS LTD·Filed 2004·Granted May 25, 2010·5 cites·6 claims
- 0367US2024294922A1Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathiesROGCON INC·Filed 2024·Application pending·0 cites
- 0464US12259378B2Dynamic clamps and methods of use thereofPRAXIS PREC MEDICINES INC·Filed 2019·Granted Mar 25, 2025·0 cites·7 claims
- 0563US2025179503A1Methods of using oligomeric compounds to treat scn2a-related disordersPRAXIS PREC MEDICINES INC·Filed 2023·Application pending·0 cites
- 0660US2025002912A1Compositions and methods for the treatment of pcdh19 related disordersTHE FLOREY INST OF NEUROSCIENCE AND MENTAL HEALTH·Filed 2022·Application pending·0 cites
- 0759US2025389712A1Dynamic clamps and methods of use thereofPRAXIS PREC MEDICINES INC·Filed 2025·Application pending·0 cites
- 0858US2025345345A1Methods for the treatment of neurological disordersPRAXIS PREC MEDICINES INC·Filed 2023·Application pending·0 cites
- 0957US11939582B2Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathiesROGCON INC·Filed 2019·Granted Mar 26, 2024·0 cites·14 claims
- 1053US2009304747A1Use of dmso and botulinum toxin therapy for urinary incontinence and related disordersMAYO FOUNDATION·Filed 2007·Application pending·0 cites
- 1153US2023174984A1Compositions and methods for treating disorders associated with loss-of-function mutations in syngap1The Florey Indtitute of Neuroscience and Mental Health·Filed 2021·Application pending·0 cites
- 1251US11713463B2Compositions and methods for increasing expression of SCN2ATHE FLOREY INST OF NEUROSCIENCE AND MENTAL HEALTH·Filed 2019·Granted Aug 1, 2023·0 cites·7 claims
- 1350US2023272387A1Compositions and methods for treating disorders associated with loss-of-function mutations in scn2aTHE FLOREY INST OF NEUROSCIENCE AND MENTAL HEALTH·Filed 2021·Application pending·0 cites
- 1449US2022090087A1Antisense oligonucleotides targeting scn2a retained intronsTHE FLOREY INST OF NEUROSCIENCE AND MENTAL HEALTH·Filed 2020·Application pending·0 cites
- 1546US2010196874A1method of drug designPICORAL PTY LTD·Filed 2007·Application pending·0 cites
- 1645US2022056455A1Compositions and methods for the treatment of kcnt1 related disordersPRAXIS PREC MEDICINES INC·Filed 2019·Application pending·0 cites
- 1742US2011294155A1Modulation of an ion channel or receptorPETROU STEVEN·Filed 2009·Application pending·0 cites
- 1841US2020129538A1Compositions and methods for treating conditions associated with gain-of-function mutations in kcnt1THE FLOREY INST OF NEUROSCIENCE AND MENTAL HEALTH·Filed 2018·Application pending·0 cites
- 1936US8288096B2Diagnostic method for epilepsyPETROU STEVEN·Filed 2010·Granted Oct 16, 2012·0 cites·5 claims
- 2036US2010088778A1Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A GeneMULLEY JOHN CHARLES·Filed 2006·Application pending·0 cites
- 2132US11124550B2Proteinaceous molecules and methods of useUNIV QUEENSLAND·Filed 2016·Granted Sep 21, 2021·0 cites·29 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →